Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial

ConclusionThe combination was relatively well tolerated, with no additional observed toxicity to single-agent lenalidomide.

Source: Clinical Lymphoma Myeloma and Leukemia - March 7, 2019 Category: Cancer & Oncology Source Type: research